| Company Name: | Amarin Corporation PLC | | Ticker Symbol: | AMRN | | | WWW Address: | www.amarincorp.com |
| CEO: | Joseph S. Zakrzewski | | No. of Employees: | 111 |
| Common Issue Type: | AD | | Business Description: | Amarin Corporation PLC is a biopharmaceutical company that commercializes and develops therapeutics to improve cardiovascular health.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 6.8 |  -0.125 | 6.8 | 6.81 | 6.84 | 7.01 | 6.75 | 1617064 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 1,022.1 | 150.3 | 1.47 | -1.24 | 0.00 | 0.0 | 0.0 | 15.96 - 6.34 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 6.92 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 1,022.1 | mil |
| Latest Shares Outstanding | 150.3 | mil |
| Earnings pS (EPS) | -1.24 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 3,546.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 3,248.10 | % |
| Gross Profit Margin | 45.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -108.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -164.8 | % |
| Current Ratio | 5.7 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 134.0 | % |
| Working Capital pS | 1.33 | $ |
| Cash pS | 1.34 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.47 | $ |
| Cash Flow pS | -1.85 | $ |
| Free Cash Flow pS | -1.18 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -14.59 | |
| Price/Cash Flow | -3.7 | |
| Price/Free Cash Flow | -5.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.1 | 98 | 38,382 | 111,184 |
| 4 Weeks | 7.98 | 6.71 | 6.84 | 1.2 | 97 | 38,260 | 726,938 |
| 13 Weeks | 8.77 | 6.34 | 8.24 | -16.0 | 77 | 36,660 | 2,309,594 |
| 26 Weeks | 12.90 | 6.34 | 11.21 | -38.3 | 53 | 41,012 | 5,085,480 |
| 52 Weeks | 15.96 | 6.34 | 11.55 | -40.1 | 48 | 48,527 | 12,034,662 |
| YTD | 9.24 | 6.34 | - | -14.5 | 74 | 37,283 | 3,691,064 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 7.00 | 7.21 | 7.20 | 8.56 | 9.74 | 1.47 | 0.91 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 7.54 | NA | 430.60 |
| R&D | 34.92 | NA | 42.07 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.0 | 0.0 | 0.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.24 | 0.24 | -0.71 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 83.80 |
| Current Ratio | 11.3 |
| Quick Ratio (Acid Test) | 10.3 |
| Liquidity Ratio (Cash) | 10.33 |
| Receivables Turnover | 0.0 |
| Average Collection Period | |
| Working Capital/Equity | -6517.2 |
| Working Capital pS | 1.73 |
| Cash-Flow pS | -1.10 |
| Free Cash-Flow pS | -0.90 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 0.43 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 101.3 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 134.5 |
| LT Debt/Total Liabilities | 69.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 6.33 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 8.53 |
| Tobin's Q Ratio | 3.35 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -9.38 |
| Enterprise Value (EV)/Free Cash Flow | -5.78 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -14.59 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -3.7 |
| Price/Free Cash Flow Ratio - LTM | -5.9 |
| Price/Sales Ratio | 444.32 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 6.8 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 1.46 |
| Current Liabilities pS | 0.17 |
| Tangible Book Value pS - LTM | -0.47 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 1.43 |
| Cash pS - LTM | 1.34 |
| Cash Flow pS - LTM | -1.85 |
| Free Cash Flow pS - LTM | -1.18 |
| Earnings pS (EPS) | -1.24 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.00 |
| Free Cash Flow Margin 5YEAR AVG | 0.00 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -83.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -675.7 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -57.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | -102.1 |
| Gross Profit Margin | 45.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | -5.0 |
| Effective Tax Rate - 5YEAR AVRG. | -0.9 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | |
| Revenue per Employee | |
| Net Income per Employee | -1,614,270 |
| Average Collection Period | |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 0.00 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.00 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.00 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |
